ANRO
HealthcareAlto Neuroscience, Inc.
$16.53
$-0.06 (-0.36%)
Jan 5, 2026
Price History (1Y)
Analysis
Alto Neuroscience, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $513.53M and 76 employees, it is a relatively small player in its industry. The company's financial performance indicates significant losses, with net income totaling -$62,257,000 and EBITDA at -$65,632,000 over the trailing twelve months. Free cash flow also shows a substantial deficit of $-36,611,124. However, Alto Neuroscience has maintained positive cash reserves of $137.82M while carrying relatively low debt of $25.40M. The company's valuation metrics are negative, with a forward P/E ratio of -7.76 and an EV/EBITDA ratio of -6.14. The price to book ratio stands at 4.03. Margins, including gross, operating, and profit margins, are all at 0.0%. Returns on equity and assets are also negative, with ROE at -45.0% and ROA at -24.5%, respectively.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Visit website →Key Statistics
- Market Cap
- $513.53M
- P/E Ratio
- N/A
- 52-Week High
- $20.91
- 52-Week Low
- $1.60
- Avg Volume
- 748.16K
Company Info
- Industry
- Biotechnology
- Exchange
- NYQ
- Country
- United States
- Employees
- 76